Unlock instant, AI-driven research and patent intelligence for your innovation.

Method of inhibiting apolipoprotein-e expression comprising administering a triarylmethyl amine compound

a technology of triarylmethyl amine and apolipoprotein, which is applied in the direction of biocide, tumor/cancer cells, artificial cell constructs, etc., can solve the problems that alzheimer's disease will continue to be a major and expensive health crisis

Active Publication Date: 2014-01-02
CALIFORNIA STATE UNIV FRESNO
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is related to a method for inhibiting the expression of apolipoprotein E (apoE) in mammalian cells. The invention is achieved by administering a triarylmethyl amine compound having a specific formula (I). The invention aims to provide a treatment for diseases associated with high levels of apoE such as Alzheimer's disease. The method can be applied to human cells, including brain cells. The technical effect of the invention is the reduction of apoE expression which can lead to improved treatment outcomes for Alzheimer's disease and related disorders.

Problems solved by technology

Alzheimer's Disease will continue to be a major and expensive health crisis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of inhibiting apolipoprotein-e expression comprising administering a triarylmethyl amine compound
  • Method of inhibiting apolipoprotein-e expression comprising administering a triarylmethyl amine compound
  • Method of inhibiting apolipoprotein-e expression comprising administering a triarylmethyl amine compound

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Triarylmethyl amine 4-(Naphthalen-2-yl-diphenyl-methyl)-morpholine (Shown as Compound 33 in Table 1)

[0043]Scratched magnesium turnings (1.056 g, 43.4 mmol) were placed in a 250 mL round-bottomed, 3-neck flask at room temperature. A small portion of the solution of 2-bromonaphthalene (11.84 g, 47.7 mmol) in anhydrous ether (40 mL) was added through an addition funnel and the solution was heated to gentle reflux maintaining the temperature at 35° C. The rest of the solution was added in small fractions over a period of 1 hour, and the resulting reaction mixture was refluxed for an additional 1 hour. Disappearance of all magnesium indicated the completion of the reaction.

[0044]The solution containing benzophenone (7.04 g, 38.6 mmol) in anhydrous ether (20 mL) was added through an additional funnel all at once over 2-4 minutes. The resulting reaction was gently refluxed for 24 hours. The cooled mixture was slowly and carefully quenched by adding aqueous HCl (6M) to the rea...

example 2

Synthesis of Triarylmethyl amine: Diethyl-[(4-methoxy-phenyl)-diphenyl-methyl]-amine (Shown as Compound 17 in Table 1)

[0047]The reaction was carried out on a 1 / 10th scale compared to EXAMPLE 1, starting with scratched magnesium turnings (0.110 g, 4.3 mmol) placed in a 250 mL round-bottomed, 3-neck flask at room temperature. A small portion of the solution of 2-bromonaphthalene (1.18 g, 47.7 mmol) in anhydrous ether (4 mL) was added through an addition funnel and the solution was heated to gentle reflux maintaining the temperature at 35° C. The rest of the solution was added in small fractions over a period of 1 hour, and the resulting reaction mixture was refluxed for an additional 1 hour. Disappearance of all magnesium indicated the completion of the reaction.

[0048]The solution containing benzophenone (0.7 g, 38.6 mmol) in anhydrous ether (2 mL) was added through an additional funnel over 2-4 minutes. The resulting reaction was gently refluxed for 24 hours. The cooled mixture was ...

example no.3

EXAMPLE NO. 3

Triarylmethyl Amine Compounds Administered to Human CCF-STTG1 Astrocytoma Cells and Analyzed by ELISA

[0060]To obtain the data shown in Table 2, Table 3, and FIG. 2, the human CCF-STTG1 astrocytoma cells (ATCC, CRL-1718) were maintained in RPMI medium (Mediatech) supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g / L glucose, 1% penicillin / streptomycin, and 10% bovine growth serum (HyClone) at 37° C. with 5% CO2.

[0061]All triarylmethyl amine compounds listed in Table 1 were individually dissolved in DMSO at a stock concentration of 10 mM and individually tested. For ELISA's, 1.6×104 cells / 96-well were grown for 1 day in RPMI, followed by a 24 hour equilibration in serum-free Opti-MEM (Life Technologies). Treatments were carried out in quadruplicate with 100 μL of fresh Opti-MEM containing 10 μM of compound or vehicle (0.1% DMSO) for 24 hours. Conditioned medium from these samples were then diluted 2-fold with incubation buffer (PBS+0.05% Tween-20+0.1% BSA) and anal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula:wherein the R1 group may comprise acyclic amines and aliphatic amines. The R2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells.

Description

BACKGROUND OF THE INVENTION[0001]Alzheimer's Disease is a common form of dementia associated with memory loss, intellectual function decline, depression, and disorientation. Alzheimer's Disease affects more than 5 million people in the United States and costs over $200 billion every year. (Alzheimer's Association, The Journal of the Alzheimer's Association (2012) 8: 131-168.) It is found in 13% of the population over the age of 65 and 45% of the population over the age of 85. (Alzheimer's Association, The Journal of the Alzheimer's Association (2012) 8: 131-168.) With a rapidly aging American population, prevalence of Alzheimer's Disease is expected to increase 2.5-fold to 13 million people in the United States in the next few decades. (Hebert et al., Arch Neurol (2003) 60: 1119-1122). Alzheimer's Disease will continue to be a major and expensive health crisis.[0002]Alzheimer's Disease is typified by increased deposition of amyloid beta plaques and neurofibrillary tangles in the bra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5375C12N5/079A61K31/135A61K31/4965A61K31/4453A61K31/402C12N5/071C12N5/02
CPCA61K31/135A61K31/4453A61K31/5375A61K31/40A61K31/495C12N5/0622C12N5/067C12N5/0693
Inventor MAITRA, SANTANUPATEL, NILAY
Owner CALIFORNIA STATE UNIV FRESNO